Cannabinoids Reduce cAMP Levels in Rats Through In Vivo Microdialysis

Strategic Insights -

Cannabinoid receptor subtype 1 (CB1R) plays a crucial role in the regulation of adenylyl cyclase-catalyzed cAMP production. Researchers at Eli Lilly and Company in Indianapolis have used microdialysis to monitor the effects of cannabinoids on cAMP activity in rats. The study revealed that striatal infusion of the CB1R agonist WIN55,212-2 dose-dependently decreased basal and forskolin-stimulated extracellular cAMP, which was reversed by co-infusion of the CB1R antagonist SR141716A.

Key Takeaways:

  • Researchers at Eli Lilly and Company used microdialysis to monitor the effects of cannabinoids on cAMP activity in rats.
  • The study found that CB1R agonists reduced both basal and forskolin-stimulated cAMP synthesis in cell lines and native tissue preparations.
  • Striatal infusion of the CB1R agonist WIN55,212-2 (100 mcM or 1 mM) dose-dependently decreased basal and forskolin-stimulated extracellular cAMP.
  • Co-infusion of the CB1R antagonist SR141716A (30 mcM) reversed these effects.
  • The study indicates that changes in extracellular cAMP concentrations in response to CB1R stimulation can be monitored in vivo.
  • Eli Lilly and Company researchers, including M.R. Wade and colleagues, conducted the study.
  • The study was published in Brain Research (Cannabinoids reduce cAMP levels in the striatum of freely moving rats: an in vivo microdialysis study. Brain Res, 2004;1005(1-2):117-123).

Statistics:

  • 100 mcM or 1 mM: the doses of the CB1R agonist WIN55,212-2 used in the study to decrease basal and forskolin-stimulated extracellular cAMP.
  • 30 mcM: the concentration of the CB1R antagonist SR141716A used to reverse the effects of WIN55,212-2.
  • 300 mcM: the highest concentration of SR141716A tested, which had no effect.
  • 2004: the year the study was published in Brain Research.

Sources:

  • Wade, M.R., et al. "Cannabinoids reduce cAMP levels in the striatum of freely moving rats: an in vivo microdialysis study." Brain Research, vol. 1005, no. 1-2, 2004, pp. 117-123. Elsevier Science BV.
  • Elsevier Science BV. PO Box 211, 1000 AE Amsterdam, Netherlands.